Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10128728 | 0.88 | TSHR (0.40) | TSHRTP53TDP1PPARD | |
| SCHEMBL24983983 | 0.85 | ALDH1A1 (0.40) | TSHRTP53TDP1ALDH1A1 | |
| SCHEMBL10426582 | 0.81 | TSHR (0.48) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL4434268 | 0.81 | TSHR (0.48) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL10128274 | 0.80 | TSHR (0.42) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL13657439 | 0.78 | TSHR (0.50) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL9115350 | 0.78 | TSHR (0.50) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL4757795 | 0.77 | TSHR (0.43) | TSHRTP53TDP1PPARD | |
| SCHEMBL25285395 | 0.77 | TSHR (0.43) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL5595512 | 0.77 | TSHR (0.43) | TSHRTP53TDP1PPARDACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220219-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230295197-A1 | STAT5 and STAT6 Degraders and Uses Thereof | REGENTS OF THE UNIV OF MICHICAN (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023164680-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230010358-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| EP-2057173-B1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8119617-B2 | aSMase inhibitors | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-8119617-B2 | aSMase inhibitors | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20100022482-A1 | aSMase inhibitors | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| US-20100022482-A1 | aSMase inhibitors | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| WO-2008022771-A1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022482-A1 | aSMase inhibitors | SMPD1, SMPD3, SMPD2 | TSHR 2541/4885TP53 4791/4885TDP1 1139/4885 |
| US-20230295197-A1 | STAT5 and STAT6 Degraders and Uses Thereof | STAT6, STAT5B, STAT5A | TSHR 107/4885TP53 48/4885TDP1 4111/4885 |
| US-20230010358-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | MCL1, BCL2A1, BCL2L1 | TSHR 4554/4885TP53 82/4885TDP1 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.